US 12,364,770 B2
Antibodies specific to MUC18
Bing Hou, Shanghai (CN); Guangcun Cheng, Shanghai (CN); Shaofei Zhang, Shanghai (CN); Na Wang, Shanghai (CN); Shu-Hui Liu, Redwood City, CA (US); and Xun Meng, Shanghai (CN)
Assigned to Multitude Inc., Shanghai (CN)
Filed by Multitude Inc., Shanghai (CN)
Filed on Jun. 17, 2021, as Appl. No. 17/351,014.
Application 17/351,014 is a continuation of application No. PCT/US2019/067457, filed on Dec. 19, 2019.
Claims priority of application No. PCT/CN2018/122572 (WO), filed on Dec. 21, 2018.
Prior Publication US 2022/0041749 A1, Feb. 10, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC A61K 47/6849 (2017.08) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4257 (2025.01); A61K 47/68031 (2023.08); A61K 47/6865 (2017.08); C07K 16/3092 (2013.01); G01N 33/5743 (2013.01); A61K 2239/59 (2023.05); C07K 2317/92 (2013.01)] 5 Claims
 
1. An isolated antibody that binds to human MUC18, wherein the isolated antibody comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HC CDR1) of the amino acid sequence of SEQ ID NO: 11, a HC CDR2 of the amino acid sequence of SEQ ID NO: 23, and a HC CDR3 of the amino acid sequence of SEQ ID NO: 35, and a light chain variable region (VL) comprising a light chain CDR1 (LC CDR1) of the amino acid sequence of SEQ ID NO: 45, a LC CDR2 of the amino acid sequence STS, and a LC CDR3 of the amino acid sequence of SEQ ID NO: 59.